Canine sulfonamide hypersensitivity (HS) has been associated with a variant in the cytochrome b 5 reductase gene (CYB5R3 729A>G), which encodes a drug-detoxifying enzyme. Study objectives were to determine variant allele frequency in Doberman Pinschers (DOBE), a breed which may be predisposed to sulfonamide HS, and to characterize the effects of CYB5R3 729G on gene expression and function. CYB5R3 729A>G allele frequencies were compared between DOBE (n = 24) vs. non-Doberman (non-DOBE; n = 60) dogs. CYB5R3 mRNA expression, protein expression, and reduction of sulfamethoxazole hydroxylamine were compared between banked canine liver samples of 729AA vs. GG genotype. The 729G allele was overrepresented in DOBE (1.00) vs. non-DOBE dogs (0.567, p < .0001). mRNA and protein expressions as well as cyt b 5 reductase activity were similar between livers of AA and GG genotype. All Doberman Pinschers in this study were homozygous for CYB5R3 729G, which could contribute to this breed's apparent predisposition to sulfonamide HS. However, CYB5R3 729G does not alter sulfamethoxazole detoxification capacity, so a direct role could not be demonstrated. It is possible that this marker is linked to another contributing variant.
| INTRODUCTION
Hypersensitivity (HS) to sulfonamide antibiotics is an uncommon, but potentially severe, idiosyncratic drug reaction that occurs in both dogs and humans (Trepanier, 2004) . In dogs, sulfonamide HS occurs a minimum of 5 days and an average of 12 days after initiation of antimicrobial therapy (Trepanier, Danhof, Toll, & Watrous, 2003) . The most commonly reported clinical signs include fever, blood dyscrasias, hepatopathy, and polyarthropathy, but uveitis, cutaneous and mucocutaneous lesions, proteinuria, and neurologic signs may also occur (Fox, Ford, Alleman, Homer, & Harvey, 1993; Giger, Werner, Millichamp, & Gorman, 1985; Harvey, 2006; Trepanier et al., 2003) . Treatment is largely supportive and requires withdrawal of the sulfonamide drug; our previous retrospective study found a mortality rate of 21%, with hepatopathy and thrombocytopenia carrying a poorer prognosis (Trepanier et al., 2003) .
As an idiosyncratic drug reaction, the occurrence of sulfonamide HS is inherently difficult to predict. However, in humans, the condition appears to be heritable (Mohanasundaram, Rajaram, & Mohanasundaram, 1998; Neuman, Malkiewicz, & Shear, 2000; Shear, Spielberg, Grant, Tang, & Kalow, 1986) , and, in dogs, breeds such as the Doberman Pinscher appear to be overrepresented (Cribb, 1989; Cribb & Spielberg, 1990; Giger et al., 1985; Gray, 1990; Werner & Bright, 1983; Whur, 1987) . These findings suggest that a genetic predisposition to sulfonamide HS may be present for both species.
Our laboratory has previously identified a genetic risk factor for sulfonamide HS in dogs: a single-nucleotide polymorphism (SNP) in the CYB5R3 gene (729A>G) (Funk-Keenan et al., 2012) . CYB5R3 encodes for cytochrome b 5 reductase, a hepatic microsomal enzyme that detoxifies the sulfonamide hydroxylamine drug metabolite, which is thought to be involved in the pathogenesis of the HS reaction (Cribb & Spielberg, 1990 ). In our previous study, the GG genotype was significantly overrepresented in dogs with sulfonamide HS compared to dogs tolerant to a course of sulfonamide antibiotics. The CYB5R3 729A>G variant is a synonymous coding SNP, but is predicted to alter the conformation of the mRNA transcript to a more stable form (Funk-Keenan et al., 2012) . We therefore hypothesized that CYB5R3 729G might lead to impaired mRNA translation, decreased enzyme synthesis, and diminished sulfonamide hydroxylamine reduction activity.
The goal of this study was to better understand the role of CYB5R3 729A>G as a genetic risk factor for sulfonamide HS in dogs. The specific objectives of this study were to determine whether CYB5R3 729G is overrepresented in Doberman Pinschers and to evaluate the effects of the CYB5R3 729G allele on gene expression and enzyme activity.
| METHODOLOGY

| Genotyping study
| Study population and sample collection
To determine the prevalence of this variant in an overrepresented breed, allele and genotype frequencies were compared between Doberman Pinschers (DOBE) and dogs of other breeds (non-DOBE).
Whole blood (EDTA or heparin) or buccal mucosal swabs were collected from dogs at the University of Wisconsin Veterinary Medical Teaching Hospital (UW-VMTH) patient population, from dogs owned by School of Veterinary Medicine students, faculty, and staff, at outreach events at local dog training facilities, and through Doberman Pinscher interest group message boards and listservs. All dogs in the DOBE and non-DOBE groups were reported by their owners to be naïve to sulfonamide antibiotics.
Samples were also collected from additional dogs with sulfonamide HS and dogs tolerant to a course of sulfonamide antibiotics (TOL).
These dogs were recruited through the UW-VMTH or through referral consultation with one of the authors (LT) between 2014 and 2017.
All dogs in these groups had received a therapeutic course of potentiated sulfonamide antibiotics. Dogs were included in the HS group if hepatopathy, blood dyscrasia, polyarthropathy, fever, or skin eruption developed 5 days or longer after initiation of antibiotic therapy and no other plausible explanation for these clinical signs was present. Dogs were included in the TOL group if they completed at least a 14-day course of potentiated sulfonamide antibiotics without developing adverse reactions. CYB5R3 729A>G genotyping results from these dogs were combined with those of previously reported HS and TOL dogs (n = 34) (Funk-Keenan et al., 2012) and analyzed as a single study population. The study protocol was approved by the University of Wisconsin's Institutional Animal Care and Use Committee (Protocol # V01478-0-02-13).
| Genotype determination
Genomic DNA was extracted from blood or buccal swab with a commercial kit (DNEasy Blood and Tissue Kit; Qiagen, Hilden, Germany) and quantified and checked for quality via spectrometry (Take3; BioTek Instruments Inc., Winooski, VT). The region around the 
| Functional studies
The hypothesis that CYB5R3 729G leads to a more stable and difficult to translate mRNA transcript, thus decreasing protein expression and total enzyme function, was initially investigated in genotyped canine liver samples. The functional implications of this variant were also assessed in an in vitro cell transfection and expression system.
| Canine hepatic CYB5R3 expression and function
Genomic DNA was extracted from banked livers of 46 dogs of varying breeds (no Dobermans included) and genotyped for CYB5R3 729A>G.
The dogs included 24 from our laboratory (18 purpose bred hounds and 6 beagles) and 22 provided by Dr. Michael Court at Washington State University (nine mixed breed dogs, five Greyhounds, four Chihuahuas, three Beagles, and one Labrador Retriever). Livers with homozygous AA and GG genotypes were used to compare CYB5R3 mRNA expression, microsomal cytochrome b 5 reductase (b5R) protein expression, and microsomal sulfamethoxazole-hydroxylamine reduction activity. mRNA expression was determined using qRT-PCR: total RNA was extracted from canine livers with a commercial kit (RNEasy Mini Plus; Qiagen, Hilden, Germany) and digested for genomic DNA (TURBO DNA-free; Thermo Fisher Scientific, Madison, WI). RNA was quantified (Take3; BioTek Instruments Inc., Winooski, VT) and assessed for quality (2100 Bioanalyzer; Agilent Technologies, Santa Clara, CA); all samples had RNA integrity numbers of six or greater (Fleige & Pfaffl, 2006) . cDNA was generated from 500 ng of RNA via reverse transcription with random oligomers (Superscript IV VILO cDNA Synthesis Kit; Thermo Fisher Scientific; Madison, WI). Primers were designed for the canine CYB5R3 transcript along with two canine reference genes (B2M, HPRT1, Data S1) and primer efficiencies determined for each using a 10-fold dilution series of pooled cDNA. SYBR Green (LightCycler 480 SYBR Green I Master; Roche Diagnostics; Indianapolis, IN) qPCR with melting curves was performed on the LightCycler 96 Instrument (Roche Diagnostics) with parameters adapted from manufacturer's directions. mRNA expression data were reported as normalized ratios.
For quantification of b5R protein expression and enzyme function, canine liver microsomes were prepared using ultracentrifugation.
Protein expression was determined by immunoblotting using calnexin as a loading control. For each sample, 0.625 μg of microsomal protein was electrophoresed in polyacrylamide and transferred onto a nitrocellulose membrane. This loading amount yielded adequate resolution for relative quantification for all target proteins. Membranes were blocked in 5% bovine serum albumin (Sigma-Aldrich; St. Louis, MO) for 1 hr, washed in 0.1% PBS-Tween, and then incubated with polyclonal rabbit anti-dog calnexin antibody (1:2,000; ab75801, Abcam, Cambridge, United Kingdom) and polyclonal rabbit anti-human b5R antibody (1:20,000) (Kurian, Bajad, Miller, Chin, & Trepanier, 2004) for 1 hr at room temperature. The membrane was washed three times and incubated with horseradish peroxidase-conjugated rabbit anti-IgG antibody (1:5,000; Promega Corp., Fitchburg, WI) in 1% milk for 1 hr at room temperature and washed again. Protein bands were detected by chemiluminescence (ECL Western Blotting Detection Reagent; GE Healthcare, Buckinghamshire, United Kingdom). Band densitometry was assessed using ImageJ (National Institutes of Health, Bethesda, MD), and protein expression was reported as b5R:calnexin density ratio.
Microsomal b5R enzyme activity was assessed by measuring reduction of sulfamethoxazole hydroxylamine (SMX-HA; Dalton Chemical Co., Toronto, Ontario, Canada) to sulfamethoxazole (SMX; SigmaAldrich; St. Louis, MO) by HPLC as previously described, (Trepanier & Miller, 2000) using 125 μg microsomal protein and 200 μM SMX-HA.
Enzyme activities were expressed as nmoles SMX generated/mg microsomal protein/min.
| In vitro canine CYB5R3 expression
The full length CYB5R3 cDNA sequence was amplified from the liver cDNA of a dog homozygous for the reference 729A allele and 12.5 ± 6.6%, p = .33 using a Student's t test).
Following cell transfection and incubation, RNA was extracted from HepG2 cells for cDNA generation and protein was extracted for quantification. mRNA expression was assessed by qPCR using primers for canine CYB5R3 with human B2M and HMBS as reference genes (Data S1). Protein was extracted from separate cell culture preparations using passive lysis buffer (Promega Corp., Fitchburg, WI) and quantified via immunoblotting. For each sample, 2.5 μg of lysate protein was electrophoresed in polyacrylamide and transferred onto a nitrocellulose membrane. Membranes were blocked in 5% bovine serum albumin for 1 hr, washed, and incubated with anti-mouse β-actin monoclonal antibody conjugated with horseradish peroxidase (1:5,000; ab20272, Abcam, Cambridge, United Kingdom) for 1 hr at room temperature. β-actin protein bands were detected by chemiluminescence, and then, the membrane was stripped (Restore PLUS Western Blot Stripping Buffer; ThermoScientific, Rockford, IL). The membrane was incubated with polyclonal rabbit anti-human b5R antibody (1:50,000 in 1% milk) for 1 hr at room temperature, followed by horseradish peroxidase conjugated (1:5,000 in 1% milk) for 1 hr at room temperature and detection of b5R protein bands. Band densitometry was assessed using ImageJ, and protein expression was reported as b5R:β-actin density ratio.
| Statistical analyses
Continuous data were expressed as median [range] . Differences in age and sex between groups were compared with the Mann-Whitney U and chi-square tests, respectively. Allele and genotype frequencies were compared between groups using Fisher's exact and chi-square tests, respectively. Expression levels and activities were compared between AA vs. GG genotype livers and A-vs. G-plasmid-transfected cells using the Mann-Whitney U test. All analyses were performed using commercial software (Prism; GraphPad Software Inc., San Diego, CA). Statistical significance was set at p < .05.
| RESULTS
| Genotyping
Eighty-four dogs were included in the breed comparison of allele frequencies (24 DOBE and 60 non-DOBE). Demographic data are reported in Table 1 . There was no significant difference in age (p = .08) between DOBE and non-DOBE dogs. However, intact animals were overrepresented in the DOBE group compared to the non-DOBE group (p = .0005). The G allele was significantly over represented in DOBE dogs (1.00) compared to non-DOBE dogs (0.567, p < .0001, Table 1 ). Similarly, the GG genotype was overrepresented in DOBE dogs (1.00) compared to non-DOBE dogs (0.417, p < .0001). CYB5R3 729A>G allele and genotype frequencies were also compared be- 
| Functional effects of CYB5R3 729G: canine liver expression and activity
Forty-six banked dog livers of adequate RNA quality were available for analysis. Of these, 12 were 729AA and 15 were 729GG; 19 were heterozygotes that were not further phenotyped. Expression of CYB5R3 mRNA was not significantly different between AA and GG livers (normalized ratio, 1.16 [0.17 -1.62] vs. 0.97 [0.19 -1.72 ], p = .17, Figure 1a) . Similarly, there was no significant difference be- Non-DOBE n = 60 HS n = 24 TOL n = 20
Age ( nmol/min/mg, p = .373, Figure 1c ).
| Functional effects of CYB5R3 729G: in vitro expression
In transfection experiments, there was no significant difference in ex- 
| DISCUSSION
Cytochrome b 5 reductase, along with cytochrome b 5 , catalyzes the reduction of the reactive sulfonamide metabolite, SMX hydroxylamine, back to the stable parent drug (Kurian et al., 2004; Trepanier & Miller, 2000) . As the hydroxylamine metabolite contributes to the immunogenicity of sulfonamide antibiotics such as sulfamethoxazole and sulfadiazine (Cribb & Spielberg, 1990; Farrell et al., 2003; Shear & Spielberg, 1985) , hydroxylamine reduction should be protective against sulfonamide HS. Dogs may rely more heavily on the cytochrome b 5 reductase system for sulfonamide detoxification, because dogs lack the other major detoxifying pathway employed by humans, the N-acetyltransferases (Trepanier, Ray, Winand, Spielberg, & Cribb, 1997) .
We previously examined the role of variants in the cytochrome b 5 reductase (CYB5R3) and cytochrome b 5 (CYB5A) genes in the risk of sulfonamide HS in dogs. We found a synonymous SNP in the CYB5R3 gene, 729A>G, that was significantly associated with sulfonamide HS in a group of 18 affected and 16 control dogs (Funk-Keenan et al., 2012) . The purpose of this study was to determine whether the risk allele was overrepresented in Doberman Pinschers, and to evaluate the effects of the CYB5R3G allele on gene expression and enzyme activity. ) ; thus, the G allele may indeed predispose to sulfonamide HS. However, it is important to note that 30% of tolerant dogs are still homozygous for 729GG. Therefore, it follows that carriage of the CYB5R3 729G allele is not sufficient as a single risk factor for sulfonamide HS.
We next investigated the effects of CYB5R3 729G on gene expression and activity in both canine liver and an in vitro mammalian expression system. The CYB5R3 729A>G variant is a synonymous coding SNP, so it should not affect enzyme structure or function. However, based on in silico predictions, the G allele may confer a more stable and difficult to translate structure to the mRNA transcript (FunkKeenan et al., 2012) . Therefore, we hypothesized that 729G might lead to increased mRNA levels but decreased protein synthesis and SMX-HA reduction.
We found no differences in CYB5R3 mRNA or b5R protein expression between canine livers of 729AA vs. GG genotype. However, the loading control (calnexin) used for immunoblotting was somewhat variable between samples, so b5R protein immunoreactivity was analyzed without normalization. These results also showed no significant difference in b5R expression between groups (p = .075), and even if these findings were significant, the small difference in expression (~25% decrease in GG livers) is unlikely to have a pharmacologically meaningful effect on drug metabolism. This is corroborated by endogenous SMX-hydroxylamine reduction, which did not differ between genotypes, even at lower substrate concentrations (10 μM SMX hydroxylamine, data not shown). In addition, a direct effect of the 729G allele on protein expression was not confirmed by in vitro transfection in HepG2 cells. Of note, cytochrome b 5 reductase activity could not be reliably measured in transfected HepG2 cells over background activities observed in nontransfected cells (data not shown), which may reflect a requirement for parallel cotransfection of CYB5A at an optimized stoichiometry (Kurian et al., 2004) , which was not pursued.
Taken together, we found no evidence that the CYB5R3 729G allele decreases SMX-hydroxylamine reduction and detoxification.
However, this allele is associated with a HS clinical phenotype in dogs.
This could be a false positive association, or this variant could be in linkage disequilibrium with another gene locus which does cause functional alterations that influence clinical phenotype.
This study was limited by a small sample size for genotyping experiments. As an idiosyncratic reaction, sulfonamide HS is intrinsically an uncommon occurrence (Noli, Koeman, & Willemse, 1995) ; furthermore, sulfonamides are less commonly used today because other antibiotics with lower risks of adverse effects are available.
However, as antimicrobial resistance to "safer" antibiotics (e.g., beta-lactams and fluoroquinolones) increases, we may see increased sulfonamide use and a resurgence of HS reactions. Therefore, it is important to understand this idiosyncratic reaction and its risk factors as best as possible.
In conclusion, all Doberman Pinschers genotyped were homozygous for the CYB5R3 729G allele, which is overrepresented in dogs with sulfonamide HS. However, we could find no evidence that this variant leads to functionally impaired detoxification of sulfamethoxazole hydroxylamine. Further work is needed to explore risk factors for sulfonamide HS in dogs.
